Spironolactone for heart failure with preserved ejection fraction.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of spironolactone in patients with heart failure and a preserved left ventricular ejection fraction.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): N Engl J Med

Title: The New England journal of medicine

Publisher: Massachusetts Medical Society

ISSN (Electronic): 1533-4406

ISSN (Print): 0028-4793

Publication date (Electronic): Apr 10 2014

Volume: 370

Issue: 15

Affiliations

[1 ] From the University of Michigan School of Medicine, Ann Arbor (B.P.); the Cardiovascular Division, Brigham and Women's Hospital, Boston (M.A.P., B.C., A.S.D., E.F.L., S.D.S.); New England Research Institutes, Watertown, MA (S.F.A., B.H., C.T.K., S.M.M.); National Heart, Lung, and Blood Institute, Bethesda, MD (R.B., J.L.F., S.Y.); Veterans Affairs Medical Center and University of Minnesota, Minneapolis (I.S.A.); Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil (N.C.); Estudios Clinicos Latinoamerica, Rosario, Argentina (R.D.); Pirogov Russian National Research Medical University, Moscow (I.G.); New York Methodist Hospital, Brooklyn (J.F.H.); Montreal Heart Institute, Montreal (E.O.); University of Washington Medical Center, Seattle (J.L.P.); Diagnostic Services Clinic, Tbilisi, Georgia (T.S.); Northwestern University, Chicago (S.J.S.); and the University of Wisconsin, Madison (N.K.S.).

Article

DOI: 10.1056/NEJMoa1313731

PubMed ID: 24716680

SO-VID: 9cf7e07a-f0ff-4972-89f9-9c922cb81005

History

Data availability:

Comments

Comment on this article

scite_

Cited by 727

See all cited by

- Version 1
- Version 1